Panic hits AVEO investors on SEC subpoena revelation
This article was originally published in Scrip
Executive Summary
Investors could not run fast enough from AVEO Pharmaceuticals shares in after-hours trading on 11 July after the company disclosed in a brief Securities and Exchange Commission (SEC) filing the firm had received a subpoena from the agency for documents and information about its FDA-rejected drug tivozanib.